| Literature DB >> 25765342 |
Nurul Izzati Hamzan1, Chan Yean Yean1, Rosliza Abdul Rahman1, Habsah Hasan1, Zaidah Abdul Rahman2.
Abstract
Background : Antibiotic resistance among Enterobacteriaceae posts a great challenge to the health care service. The emergence of carbapenem-resistant Klebsiella pneumoniae (CRKP) is attracting significant attention due to its rapid and global dissemination. The infection is associated with significant morbidity and mortality, thus creating challenges for infection control and managing teams to curb the infection. In Southeast Asia, there have been limited reports and subsequent research regarding CRKP infections. Thus, the study was conducted to characterize CRKP that has been isolated in our setting. Methods : A total of 321 K. pneumoniae were included in the study. Each isolate went through an identification process using an automated identification system. Phenotypic characterization was determined using disk diffusion, modified Hodge test, Epsilometer test, and inhibitor combined disk test. Further detection of carbapenemase genes was carried out using polymerase chain reaction and confirmed by gene sequence analysis. Results : All together, 13 isolates (4.05%) were CRKP and the majority of them were resistant to tested antibiotics except colistin and tigercycline. Among seven different carbapenemase genes studied (blaKPC, bla IMP, bla SME, bla NDM, bla IMI, bla VIM, and bla OXA), only two, bla IMP4 (1.87%) and bla NDM1 (2.18%), were detected in our setting. Conclusion : Evidence suggests that the prevalence of CRKP in our setting is low, and knowledge of Carbapenem-resistant Enterobacteriaceae and CRKP has improved and become available among clinicians.Entities:
Keywords: Klebsiella pneumoniae; Modified Hodge test; carbapenem-resistant Enterobacteriaceae; carbapenemase
Mesh:
Substances:
Year: 2015 PMID: 25765342 PMCID: PMC4357264 DOI: 10.3402/ehtj.v8.26011
Source DB: PubMed Journal: Emerg Health Threats J ISSN: 1752-8550
Antibiotic susceptibility patterns of Carbapenem-resistant Klebsiella pneumoniae (CRKP)
| Antibiotic tested and zone of inhibition (mm) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||||
| Isolate | ETP | MEM | IPM | SXT | AK | CN | NET | TZP | AMC | CIP | FEP | CTX | CAZ | CXM |
| 1 | 15 | 14 | 19 | 6 | 22 | 20 | 21 | 24 | 12 | 19 | 13 | 6 | 6 | 6 |
| 2 | 14 | 15 | 18 | 6 | 20 | 18 | 17 | 19 | 11 | 16 | 10 | 6 | 6 | 6 |
| 3 | 7 | 11 | 10 | 6 | 13 | 6 | 8 | 6 | 6 | 10 | 6 | 6 | 6 | 6 |
| 4 | 15 | 15 | 19 | 6 | 23 | 19 | 17 | 22 | 11 | 19 | 10 | 6 | 6 | 6 |
| 5 | 14 | 14 | 15 | 6 | 19 | 17 | 15 | 21 | 11 | 14 | 8 | 6 | 6 | 6 |
| 6 | 17 | 14 | 18 | 6 | 21 | 15 | 19 | 25 | 14 | 20 | 16 | 9 | 6 | 6 |
| 7 | 11 | 13 | 15 | 6 | 17 | 6 | 6 | 6 | 9 | 6 | 9 | 6 | 6 | 6 |
| 8 | 14 | 15 | 18 | 26 | 6 | 6 | 6 | 6 | 10 | 6 | 11 | 6 | 6 | 6 |
| 9 | 7 | 7 | 7 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| 10 | 12 | 14 | 17 | 6 | 6 | 6 | 6 | 6 | 8 | 6 | 9 | 6 | 6 | 6 |
| 11 | 10 | 12 | 14 | 6 | 6 | 10 | 6 | 6 | 6 | 9 | 6 | 6 | 6 | 6 |
| 12 | 12 | 16 | 17 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| 13 | 14 | 14 | 17 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 10 | 6 | 6 | 6 |
ETP, ertapenem; IMP, imipenem; MEM, meropenem; SXT, trimethoprim–sulfamethoxazole; AK, amikacin; CN, gentamicin; NET, netilmycin; TZP, piperacillin–tazobactam; AMC, amoxicillin–clavulanate; CIP, ciprofloxacin; FEP, cefepime; CTX, cefotaxime; CAZ, ceftazidime; CXM, cefuroxime.
List of GeneBank accession numbers for bla NDM1 and bla IMP4 reference
| Beta lactamase genes | GenBank Accession No. |
|---|---|
|
| KC539432.1; KC539430.1; KC310727.1; JF798499.1; KF016990.1; AP012055.1; JN157804.1 |
|
| JX517203.1; KF250428.1; KF184388.1; JX457479.1; JN106667.1; AJ609296.3; FJ384365.1 |
Summary of phenotypic and genotypic characteristics of carbapenem-resistant K. pneumoniae
| MIC (µg/ml) of carbapenem | ||||||
|---|---|---|---|---|---|---|
|
| ||||||
| Isolate | IPM | MEM | MHT | CD-APB | CD-EDTA | Gene detected |
| 1 | 0.5 | 2 | + | – | + |
|
| 2 | 4 | >32 | + | – | + |
|
| 3 | >32 | >32 | + | – | + |
|
| 4 | 8 | >32 | + | – | + |
|
| 5 | 4 | >32 | + | – | + |
|
| 6 | 0.25 | 2 | + | – | + |
|
| 7 | >32 | >32 | + | – | + |
|
| 8 | >32 | >32 | + | – | + |
|
| 9 | >32 | >32 | + | – | + |
|
| 10 | 16 | 8 | + | – | + |
|
| 11 | >32 | >32 | + | – | + |
|
| 12 | 16 | 8 | + | – | + |
|
| 13 | >32 | >32 | + | – | + |
|
MIC, minimal inhibitory concentration; IPM, imipenem; MEM, meropenem; MHT, modified Hodge test; CD-APB, combined disc with 3′ aminophenylboronic acid; CD-EDTA, combined disc with ethylene-diaminetetra-acetic acid.